
|Articles|July 1, 2004
ISTA seeks bromfenac OK; gets nod for injected hyaluronidase
Irvine, CA-ISTA Pharmaceuticals Inc. is seeking FDA approval of its bromfenac sodium ophthalmic solution 0.1% (Xibrom) for the treatment of ocular inflammation following cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Q&A: Optimizing the ocular surface for light adjustable lens technology
2
4DMT completes enrollment in 4FRONT-1, phase 3 trial of 4D-150 in AMD
3
PRIMA System: A major step in the battle against GA
4
Angiogenesis 2026: Continuous AI severity scoring could transform AMD monitoring
5




























